Erasca Inc. (NASDAQ: ERAS)
$3.23
+0.1500 ( +4.87% ) 2.9M
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Market Data
Open
$3.23
Previous close
$3.08
Volume
2.9M
Market cap
$881.20M
Day range
$3.01 - $3.31
52 week range
$1.51 - $3.31
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 11 | Jun 24, 2024 |
8-k | 8K-related | 11 | Jun 24, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |